

63885a.

The New England Journal of Medicine

Copyright, 1985, by the Massachusetts Medical Society

Volume 312

MAY 23, 1985

Number 21

EVIDENCE OF ALUMINUM LOADING IN INFANTS RECEIVING INTRAVENOUS THERAPY

AILEEN B. SEDMAN, M.D., GORDON L. KLEIN, M.D., RUSSELL J. MERRITT, M.D., PH.D., NANCY L. MILLER, M.S.,
KIM O. WEBER, B.S.N., WILLIAM L. GILL, M.D., HARISH ANAND, M.D., AND ALLEN C. ALFREY, M.D.

Abstract To investigate the possibility that premature infants may be vulnerable to aluminum toxicity acquired through intravenous feeding, we prospectively studied plasma and urinary aluminum concentrations in 18 premature infants receiving intravenous therapy and in 8 term infants receiving no intravenous therapy. We also measured bone aluminum concentrations in autopsy specimens from 23 infants, including 6 who had received at least three weeks of intravenous therapy.

Premature infants who received intravenous therapy had high plasma and urinary aluminum concentrations, as compared with normal controls: plasma aluminum, 36.78 ± 45.30 vs. 5.17 ± 3.1 μg per liter (mean $\pm$ S.D., $P < 0.0001$); urinary aluminum:creatinine ratio, 5.4 ± 4.6 vs. 0.64 ± 0.75 ($P < 0.01$). The bone aluminum concentration

was 10 times higher in infants who had received at least three weeks of intravenous therapy than in those who had received limited intravenous therapy: 20.16 ± 13.4 vs. 1.98 ± 1.44 mg per kilogram of dry weight ($P < 0.0001$). Creatinine clearances corrected for weight did not reach expected adult values until 34 weeks of gestation. Many commonly used intravenous solutions are found to be highly contaminated with aluminum.

We conclude that infants receiving intravenous therapy have aluminum loading, which is reflected in increased urinary excretion and elevated concentrations in plasma and bone. Such infants may be at high risk for aluminum intoxication secondary to increased parenteral exposure and poor renal clearance. (N Engl J Med 1985; 312: 1337-43.)

ALTHOUGH osteopenia in premature infants has been well documented, the cause of this complication remains to be determined.¹⁻⁵ It appears to be directly related to parenteral therapy, since bone accretion rates have been found to return to normal after infants were given enteral feedings supplemented with calcium, phosphorus, and vitamin D. In contrast, infants who could not tolerate enteral feeding had progressive osteopenia and fractures, which were resistant to standard therapy.^{1,5} This suggests that some substance either deleted from or given with parenteral therapy may be responsible for premature osteopenia. Since aluminum has been implicated in the pathogenesis of vitamin D-resistant osteomalacia in human beings and animals, we elected to study this element in premature infants.

Aluminum toxicity in human beings has been described in patients receiving hemodialysis; severe dementia developed, and the patients died as a result of excessive exposure to aluminum in their dialysate and

lack of normal renal excretion.⁶ Subsequently, it was realized that these patients also had fracturing osteomalacia.⁷ Another indication of the skeletal toxicity of aluminum was the demonstration of fracturing osteomalacia in animals by parenteral administration of aluminum.^{8,9}

After standards for acceptable concentrations of aluminum in dialysate had been established and dialysis units throughout the world began monitoring the amount of aluminum in their water, the incidence of dementia and fracturing bone disease dropped dramatically.¹⁰ In subsequent years, a more insidious form of bone disease has been described, which is secondary to excessive exposure to oral aluminum.¹¹⁻¹³ The effects are especially devastating in young children with compromised renal function.^{12,13} Other studies have provided further evidence that parenteral nutrition solutions contaminated with aluminum cause loading and possibly even bone disease in adults with normal renal function.^{14,15} No studies concerning aluminum loading have thus far been carried out in premature infants who are known to have a high incidence of osteopenia.

We have found high concentrations of aluminum in bone, urine, and plasma from infants receiving intravenous therapy. It seems possible that aluminum loading may be a factor in the bone disease seen in very ill neonates who have reduced renal function and have received long-term parenteral therapy with aluminum-contaminated fluids. It is not known whether

From the Departments of Pediatrics and Medicine, University of Colorado and Veterans Administration Hospitals, Denver; the Division of Gastroenterology and Nutrition, Children's Hospital of Los Angeles, University of Southern California School of Medicine, Los Angeles; and the Department of Pediatrics, Tulane University School of Medicine, New Orleans. Address reprint requests to Dr. Sedman at the Pediatric Nephrology Unit, Box 54, Outpatient, C1078, University of Michigan Medical Center, Ann Arbor, MI 48109-0010.

Supported in part by a grant (RR-69) from the General Clinical Research Centers, Programs of the Division of Research and Resources, National Institutes of Health; a grant from the Edward G. Schlieder Education Fund, New Orleans; and research funds from the Veterans Administration Medical Center.

Sedman AB, Klein GL,
Merritt RJ 1985

See also p. 1485

relatively short-term high concentrations of aluminum in plasma and bone in premature infants can reproduce the toxicity that chronic loading causes in older children and adults with chronic renal failure.

METHODS

We measured aluminum concentrations in plasma, urine, or bone in five groups of patients. Group I included 18 premature infants (≤ 37 weeks of gestation) who required admission to the intensive care unit and intravenous therapy. Plasma and urinary aluminum concentrations were measured in these 18 infants on two different occasions approximately three weeks apart; 9 were studied on the first day of life and three weeks later, and 9 were studied at a random time (11 to 42 days of age) and three weeks later. Urinary and serum creatinine levels were measured in infants who were more than one week old at the time of the study. Creatinine was not measured in infants less than one week of age, because the concentrations were thought to be a reflection of the mother's creatinine

and not that of the infant. In 13 infants complete 24-hour samples were collected at the three-week study; in the remainder of the infants 24-hour collections were incomplete and thus could not be used for calculation of clearances.

Group II included eight term infants who did not require intravenous therapy (normal controls). In four of these infants plasma and urinary aluminum concentrations were measured at one day and three weeks of age, and in the other four, aluminum concentrations were measured at one visit. Aluminum was also measured in 35 umbilical-cord plasma samples, to establish a normal base line; these values are reported with normal control measurements.

To estimate the amount of aluminum being given to and retained by infants who were receiving only intravenous therapy, we studied a third group of five infants (Group III) who had been receiving intravenous therapy for at least two weeks. Intake and excretion of aluminum in the urine were measured for a period of two or three days.

Clinical data on the three groups of infants are shown in Tables 1, 2, and 3. Parents were required to sign a standard consent form before the infants were enrolled in the prospective study.

Autopsy specimens were collected from 23 infants (age range, 0 to 7 months) and divided into two groups. Seventeen of the infants (Group IV) did not receive prolonged parenteral therapy because they died in the emergency or delivery room or within one week of hospitalization. Representative diagnoses at the time of death included the sudden infant death syndrome, severe prematurity, and congenital cardiac defect. The other six infants (Group V) had received at least three weeks (mean $\pm$ S.D., 9.6 ± 5.2) of parenteral nutrition before death (considered long-term parenteral nutrition). All these infants were under 37 weeks of gestation and required parenteral nutrition secondary to necrotizing enterocolitis, congenital malformation of the gastrointestinal tract, or severe feeding intolerance. One member of this group was a premature infant who had been discharged from the hospital at four months of age but died in the emergency room at six months, with a diagnosis of sudden infant death syndrome. The other five infants were inpatients at the time of death.

Plasma and urine samples were collected by clinical research nurses or technicians trained in study collection techniques. To avoid exogenous contamination of plasma samples until completion of the analysis, the skin was carefully cleansed with deionized water, and samples were collected in unaltered plastic containers and frozen in plastic containers. Urine samples were obtained by cleansing the skin as described above and applying a standard plastic urine-collection bag. Before 24-hour samples were collected, the bag was put in place, and urine was continuously drawn from the bag during the 24-hour period.

Specimens of bone were collected in the autopsy room and immediately frozen in plastic containers. They were later cleanly dissected, and the surface tissue that was adherent or contaminated was discarded. Twelve of the bone specimens were from the vertebral body, and eleven were from the iliac crest. All vertebral specimens were from infants who died acutely without prolonged

Table 1. Plasma and Urinary Aluminum Levels in 18 Premature Infants Receiving Parenteral Nutrition.*

INFANT NO.	GESTATION	BIRTH WEIGHT	AGE	FEEDING	PLASMA ALUMINUM	URINARY ALUMINUM	URINARY EXCRETION OF ALUMINUM	URINARY ALUMINUM: CREATININE
	wk	g	days		$\mu\text{g/liter}$		$\mu\text{g/24 hr}$	
1	28	1070	1	IV	49	29		
			22	BM/F	3	35	5.0	4.3
2	28	980	1	IV	26	260		
			22	BM/F	6	28	2.9	2.2
3	32	1060	1	IV	9	170		
			18	BM/F	9	60	10.1	4.3
4	26	760	1	IV	9	35		
			22	F	26	40	5.3	6.0
5	32	1200	1	IV	3	6		
			25	F	3	8	1.8	0.5
6	30	1460	1	IV	<2	20		
			33	F	6	137	19.5	11.4
7	33	1610	1	IV	<2	15		
			21	F	<2	<2	<2.0	0.2
8	34	1440	1	IV	<2	7		
			23	F	<2	20	3.9	1.8
9	31	1980		IV	9	35		
			24	F	3	20		1.7
10	32	1520	42	F	4	22		
			78	F	13	20	4.7	2.2
11	32	1220	17	F	46	32		
			38	F	13	16	3.5	1.6
12	28	820	16	F	3	25		2.1
			37	F	6	32		2.9
13	36	2720	11	IV	39	42		3.6
			22	F	26	15	4.0	0.9
14	37	2320	22	IV	29	90		9.8
			45	IV	29	85		9.6
15	27	750	30	IV	32	30		3.4
			51	IV	23	105		13.5
16	28	990	22	IV	20	40		5.9
			46	F	4	75		3.1
17	32	1100	16	IV	172	145		14.5
			43	F	9	23	3.8	1.9
18	33	2608	16	IV	136	68		6.7
			32	F	6	132	27.4	11.0

*Aluminum was measured on two different occasions separated by an interval of three weeks. IV denotes intravenous, BM breast milk, and F formula. To convert aluminum values to micromoles per liter, divide by 27.

intravenous therapy. Concentrations of aluminum in vertebral bone were not significantly different from levels in iliac-crest bone (2.25 ± 1.40 vs. 1.92 ± 1.44 mg per kilogram of dry weight). Therefore, the results of the bone analysis are reported without designation of the type of bone. Since normal bone histology has not been well documented in premature infants, histologic studies of bone were not performed in this study.

Plasma, bone, and urine were processed and analyzed for aluminum content, as previously described, by flameless atomic-absorption spectrophotometry.¹⁰ Urinary and serum creatinine levels were determined by standard methods.

Creatinine clearances were corrected for body weight at the time of the 24-hour urine collection. Mean values of aluminum were calculated from the higher plasma and urinary concentrations recorded for each child, if two values were obtained. Aluminum:creatinine ratios were calculated as micrograms per liter of aluminum divided by milligrams per deciliter of creatinine, to derive a number that factored out differences in concentration. Possible sources of aluminum (Tables 4 and 5) were investigated by obtaining aliquots of medications and solutions from pharmacies or formula packages. Breast milk was collected from mothers instructed to cleanse the skin carefully and express milk directly into plastic containers.

Statistical analyses were done by both parametric and nonparametric methods (Student's *t*-test and the Mann-Whitney *U* test). Values are expressed as means $\pm$ S.D. *P* values are derived from Student's *t*-test unless otherwise designated.

RESULTS

Table 1 shows the data on the premature infants with a history of intravenous therapy (Group I), including gestational age, birth weight, and age at the time of the plasma and urinary aluminum determinations, along with the type of intake at the time of measurement. Table 2 shows the data on normal infants without parenteral exposure (Group II). Plasma aluminum levels and urinary aluminum:creatinine ratios were significantly higher in Group I than in Group II: plasma aluminum, 36.78 ± 45.3 vs. 5.17 ± 3.1

Table 3. Urinary Aluminum Levels in Five Infants Receiving Intravenous Therapy for at Least Two Weeks before the Study.*

INFANT NO.	AGE mo	WEIGHT kg	ALUMINUM INTAKE $\mu\text{g}/24 \text{ hr}$	URINARY ALUMINUM $\mu\text{g}/24 \text{ hr}$	ESTIMATED RETENTION %	URINARY ALUMINUM:CREATININE
1	5.5	7.8	121	35	71	4.4
2	1.5	3.3	53	21	60	5.5
3	9.0	6.5	103	25	76	2.6
4	4.5	6.7	108	14	87	3.5
5	5.0	6.0	108	5	95	0.7

*To convert aluminum values to micromoles per liter, divide by 27.

μg per liter (1.4 ± 1.7 vs. 0.19 ± 0.11 μmol per liter) ($P < 0.0001$); aluminum:creatinine ratio, 5.4 ± 4.6 vs. 0.64 ± 0.75 ($P < 0.01$). Plasma aluminum levels and urinary aluminum:creatinine ratios in these two groups are summarized in Figure 1. The previously published normal plasma concentration in adults¹⁰ is 6 ± 3 μg per liter (0.22 ± 0.11 μmol per liter), which is not significantly different from the level in our normal infants. Aluminum concentrations in the 35 umbilical-cord plasma samples were also not significantly different from the levels in normal infants (4.5 ± 3.7 μg per liter [0.17 ± 0.14 μmol per liter]). Although toxic concentrations of aluminum in plasma have not been definitively established, a value over 100 μg per liter is consistently found in association with bone and neurologic abnormalities.^{12,16-18} Although the mean value in our infants in Group I was 36 μg per liter, Infants 17 and 18 had values of 172 and 136 μg per liter (6.4 and 4.4 μmol per liter), respectively, which were well into this presumably toxic range.

In 13 Group I patients plasma aluminum concentrations were measured while the infants were receiving intravenous therapy and then while they were receiving formula. Plasma concentrations during intravenous therapy were significantly different from the levels during formula feedings: 36.18 ± 54.57 vs. 8.08 ± 8.2 μg per liter (1.4 ± 2.0 vs. 0.3 ± 0.31 μmol per liter; $P < 0.01$, Mann-Whitney *U* test). There was no correlation between the total number of days of intravenous therapy and subsequent urinary aluminum:creatinine ratios ($r = 0.41$). Interestingly, urinary aluminum concentrations and aluminum:creatinine ratios continued to be very high in some infants (Table 1, Infants 1, 3, 6, and 18), as compared with normal values, even though the infants had not received intravenous therapy for a mean of 13 days and had normal plasma aluminum concentrations. In very premature infants, weight-corrected creatinine clearances were

Table 2. Plasma and Urinary Aluminum Levels in Eight Normal Term Infants without Exposure to Parenteral Therapy.*

INFANT NO.	AGE AT STUDY	FEEDING	PLASMA ALUMINUM $\mu\text{g}/\text{liter}$	URINARY ALUMINUM $\mu\text{g}/\text{liter}$	URINARY ALUMINUM:CREATININE
1	1 day	H ₂ O	6	15	
	23 days	H ₂ O/BM	10	70	2.4
2	1 day	F	3	9	
	21 days	F	<2	5	0.6
3	1 day	F	10	12	
	21 days	F	3	15	0.8
4	1 day	F	3	28	
	22 days	F	3	2	0.1
5	9 mo	F		20	0.13
6	2 mo	H ₂ O/BM		22	0.2
7	7 mo	F		7	0.6
8	3 mo	BM		12	0.28

*BM denotes breast milk, and F formula. To convert aluminum values to micromoles per liter, divide by 27.

Table 4. Levels of Aluminum in Commonly Administered Intravenous Solutions.*

SOLUTION	NO. OF LOTS TESTED	ALUMINUM CONTENT ($\mu\text{g/liter}$)
Potassium phosphate (3000 mmol/liter)	3	$16,598 \pm 1,801$
Sodium phosphate (3000 mmol/liter)	1	5,977
Calcium gluconate (10%)	5	$5,056 \pm 335$
Heparin (1000 units/ml)	3	684 ± 761
Heparin (5000 units/ml)	1	359
Heparin (10,000 units/ml)	1	468
Normal serum albumin (25%)	4	$1,822 \pm 2,503$
Intralipid	1	195
TPN solution (2¼% essential amino acid)	6	72 ± 59
5% Dextrose	2	72 ± 1
Sodium chloride (4000 mmol/liter)	3	6 ± 4
Potassium chloride (3000 mmol/liter)	1	6

*TPN denotes total parenteral nutrition. To convert aluminum values to millimoles per liter, divide by 27. Plus-minus values are means $\pm$ S D.

as low as 20 per cent of those in mature infants (Fig. 2). Weight-corrected creatinine clearances were directly correlated with gestational age, and by 34 weeks had reached normal adult levels (1.7 ml per minute per kilogram of body weight, Fig. 3). The highest plasma aluminum level in these infants did not correlate with creatinine clearance, suggesting that the intake of aluminum is the more important variable.

Group III infants had been receiving intravenous therapy for at least two weeks when aluminum intake and excretion studies were performed; four infants were studied for three days, and one was studied for two days (Table 3). All five infants had negligible stool output. Although stool aluminum was not measured, previous studies have shown that fecal aluminum losses are small in patients receiving parenteral nutrition.¹⁹ Aluminum intake was calculated from concentrations in matched solutions. The five infants had a mean intake of $98.6 \pm 11.56 \mu\text{g}$ ($3.6 \pm 0.43 \mu\text{mol}$) per 24 hours, with a mean excretion of $20.0 \pm 5.1 \mu\text{g}$ ($0.74 \pm 0.19 \mu\text{mol}$) per day, or 78 per cent retention. Normal adult urinary excretion of aluminum is $13 \pm 6 \mu\text{g}$ ($0.48 \pm 0.22 \mu\text{mol}$) per day.¹⁰ The aluminum:creatinine ratio was 3.3 ± 0.08 , which is significantly different from the value in normal infants: 0.64 ± 0.75 ($P < 0.01$).

Bone aluminum content in Group V (infants who had received intravenous therapy for over three weeks) was significantly higher than in Group IV (those who had received little or no intravenous therapy): 20.16 ± 13.4 vs. 1.98 ± 1.44 (0.75 ± 0.49 vs. 0.07 ± 0.05 mmol) per kilogram of dry weight ($P < 0.0001$, Fig. 3). All except one infant treated with long-term parenteral nutrition died during intravenous therapy. The infant who was discharged and died two months later from the sudden infant death syndrome had a bone aluminum concentration of 7 mg (0.26 mmol) per kilogram of dry weight — three times the normal level in infant bone. The normal bone concentration in adults¹⁰ is 3.3 ± 2.9 mg (0.12 ± 0.11 mmol) per kilogram of dry weight.

Tables 4 and 5 list the concentrations of aluminum in commonly used intravenous and oral solutions. Calcium and phosphate salts, heparin, and normal serum albumin have very high concentrations of aluminum, although there is wide variation among lots. Soy and premature-infant formulas with the highest additives of calcium and phosphate salts also have the highest aluminum concentrations. Human breast milk has the least aluminum.

Among the infants in Groups I and II, there was no correlation between plasma and urinary aluminum and the type of formula they were receiving at the time of the study. None of our infants were receiving

soy formula, which has the highest concentration of aluminum. It should be noted that normal adult concentrations of urinary aluminum¹⁰ would give an aluminum:creatinine ratio of 0.1; thus, the ratio of 0.6 in our normal infants may reflect the fact that infants absorb aluminum differently from adults.

DISCUSSION

Eight per cent of the earth's crust is composed of aluminum. Human beings are exposed to this element constantly through ingestion of water, food, and dust particles. In fact, it is estimated that an average adult ingests 3 to 5 mg of aluminum per day^{20,21} and excretes 14 μg per day in urine — presumably the amount absorbed — leaving only a small level of aluminum in the body.¹⁰ Since the gastrointestinal tract, skin, and lung provide excellent barriers to aluminum absorption and the kidney is efficient in eliminating any absorbed aluminum, the body burden of aluminum in normal persons is exceedingly low. Nonetheless, excessive aluminum accumulation can

Table 5. Levels of Aluminum in Commonly Used Oral Solutions.*

SOLUTION	NO. OF LOTS TESTED	ALUMINUM CONTENT ($\mu\text{g/liter}$)
Glucose water	1	20
Tap water (Colorado)	1	12
Well water (Colorado)	1	5
Breast milk	12	9.9 ± 6.87
Cow's milk-based formula (20 kcal/30 ml)	4	266 ± 192
Cow's milk-based formula, "premature" (24 kcal/30 ml)	4	699 ± 321
Soy formula (20 kcal/30 ml)	4	1478 ± 103
Multivitamins (liquid)	1	32
Nystatin	1	72

*To convert aluminum values to millimoles per liter, divide by 27. Plus-minus values are means $\pm$ S D.




Figure 1. Plasma Aluminum Levels (A) and Urinary Aluminum:Creatinine Ratios (B) in Normal Infants (Group II) and Premature Infants Receiving Intravenous Therapy (Group I).

Bars denote S.D. The normal values in adults are $6 \pm 3 \mu\text{g}$ per liter and 0.1, respectively. Al denotes aluminum, and Cr creatinine. To convert aluminum values to micromoles per liter, divide by 27.

occur and has been reported with both parenteral and oral exposure. Parenteral exposure has resulted in accumulation in patients receiving dialysis with aluminum-contaminated dialysate^{6,20} and in those receiving long-term parenteral nutrition with aluminum-contaminated fluids.^{14,15} Patients with chronic renal failure receiving large oral loads of aluminum in the form of phosphate-binding gels have also been found to have an increased body burden of aluminum.^{12,13,16,22}

Our study concerns another type of patient at risk for aluminum toxicity — the premature infant who is receiving intravenous therapy. Two conditions may predispose such children to aluminum loading: parenteral aluminum exposure and reduced renal function. A number of components of parenteral fluids given to premature infants, such as the calcium and phosphate salts used as additives and human albumin, have high concentrations of aluminum.

Evidence of aluminum loading in premature infants is based on our finding that aluminum in plasma or urine or both was almost uniformly increased in infants receiving parenteral therapy. Moreover, balance studies showed that the infants excreted only about 23 per cent of the intravenously administered aluminum. Additional evidence for aluminum loading comes from the finding that urinary aluminum concentrations remained well above the range found in control infants for several weeks after the termination of parenteral feeding. This finding suggests a slow unloading of tissue stores of aluminum that had accumulated during the period when the infants received parenteral nutrition. The strongest evidence for aluminum loading is the finding that the bone aluminum concentration

was 10 times higher than normal in a small group of infants who died after receiving parenteral therapy for three weeks or more.

The amount of toxicity that results from parenterally administered aluminum remains to be determined. The classic manifestations of systemic aluminum intoxication include fracturing osteomalacia, encephalopathy, and microcytic hypochromic anemia.^{6,7,23} For a variety of reasons, it is difficult to relate any of the abnormalities found in ill premature infants to aluminum intoxication. Although bone disease is common, the histologic data required for the diagnosis of osteomalacia are non-existent for premature infants. In addition, metabolic encephalopathy is a common complication of many of the other events that occur along with prematurity, including hypoxia, acidosis, and electrolyte imbalances. Finally, premature infants frequently require multiple transfusions to replace iatrogenic blood loss, precluding definitive hematologic evaluation. The facts that plasma aluminum levels in two infants exceeded




Figure 2. Correlation between Creatinine Clearance Corrected for Body Weight and Gestation at Birth.

Infants started at one fifth the clearance in adults and had normal levels at 34 weeks of gestation. Adult clearance is 1.7 ml per minute.




Figure 3. Bone Aluminum (Al) in Infants Who Did Not Receive Intravenous Therapy (Group IV) and in Those Who Had over Three Weeks of Intravenous Therapy (Group V).

Values are means $\pm$ S.D. and are expressed as milligrams per kilogram of dry weight. The normal adult value is 3.3 ± 2.9 mg per kilogram. To convert aluminum values to millimoles per kilogram, divide by 27.

100 μ g per liter — a value previously associated with toxicity in children^{12,13,16} — and that bone aluminum levels were as high as 36 mg per kilogram of dry weight suggest that parenteral aluminum loading in premature infants may have some clinical consequences.

We are less certain of the evidence for aluminum loading in premature infants given oral aluminum-containing substances. Although we have shown that many oral substances given to infants contain aluminum, we believe that our data support the fact that the gastrointestinal tract is an adequate barrier in most persons, since we did find that normal infants had plasma aluminum concentrations similar to those reported in normal adults. We also found that bone aluminum concentrations were consistently low in infants who had been fed orally but not parenterally before they died. Still, we must make note of the fact that the aluminum:creatinine ratio in normal, bottle-fed infants is approximately six times higher than that in normal adults.²¹ This relatively high ratio suggests that the gastrointestinal barrier to aluminum absorption is not fully developed in infants.

Another factor to consider is that a number of formulas, especially soy, have an aluminum content that is much higher than that found in human breast milk. In an adult, normal dietary intake of aluminum is 40 to 50 μ g per kilogram of body weight per day, whereas in an infant on soy formula, it can be as high

as 250 μ g per kilogram per day. Although it is unlikely that this amount of orally ingested aluminum could cause any toxicity, a recent report comparing soy and milk formulas found decreased mineralization in infants fed soy preparations.²⁵ Many other differences between soy and milk, such as calcium and phosphorus content and availability, may account for the mineralization defect. Although evidence is needed, it is not unwarranted to suspect possible aluminum contamination in infants receiving large oral loads of soy formula.

To conclude, even though the mechanisms are unknown, the evidence is strong that aluminum causes skeletal and neurologic toxicity in human beings. It seems possible that small children with rapidly maturing skeletal and nervous systems may be unduly susceptible to such toxicity. Although altered bone mineralization is the clinical problem that raised our concern about aluminum toxicity in infants, the possibility of neurologic toxicity must also be considered. With technological advances in medicine, the number of premature infants who require long-term intravenous support is rapidly expanding, thereby increasing the potential severity of this problem. The source of aluminum contamination in intravenous fluids is unknown, but the wide variation in aluminum concentrations in different lots of the assorted compounds suggests that contamination may occur during the processing of these materials. If this is the case, it may be relatively simple to eliminate or reduce aluminum contamination by modifying the manufacturing process. Until aluminum can be removed from these fluids, the amount of parenteral aluminum exposure leading to toxicity in infants needs to be determined, and permissible levels of exposure must be established.

We are indebted to Dr. Steve Abrams and Dan Berry for solution and tissue retrieval, to Dr. M.A. Shork and Susan Serçika for statistical assistance, to Dr. John Benson (Ross Laboratories) for his comments, and to Ruth Primas for preparation of the manuscript.

REFERENCES

1. Minton SD, Steichen JJ, Tsang RC. Bone mineral content in term and preterm appropriate-for-gestational-age infants. *J Pediatr* 1979; 95: 1037-42.
2. Greer F, Lane J, Weiner S, Mazess R. An improved technique for accurate determination of bone mineral content (BMC) and identifying disorders of bone mineral metabolism in low-birth-weight infants. *Pediatr Res* 1983; 16:163A.
3. Griscom NT, Craig JN, Neuhauser EBD. Systemic bone disease developing in small premature infants. *Pediatrics* 1971; 48:883-95.
4. Binstadt DH, L'Heureux PR. Rickets as a complication of intravenous hyperalimentation in infants. *Pediatr Radiol* 1978; 7:211-4.
5. Klein GL, Cannon RA, Ament ME, Norman AW, Coburn JW. Rickets and osteopenia with normal 25 OH vitamin D levels in infants on parenteral nutrition. *Clin Res* 1980; 28:596A.
6. Alfrey AC, LeGendre GR, Kaehny WD. The dialysis encephalopathy syndrome: possible aluminum intoxication. *N Engl J Med* 1976; 294: 184-8.
7. Parkinson IS, Ward MK, Feast TG, Fawcett RWP, Kerr DNS. Fracturing dialysis osteodystrophy and dialysis encephalopathy: an epidemiological survey. *Lancet* 1979; 1:406-9.
8. Ellis HA, McCarthy JH, Herrington J. Bone aluminum in haemodialyzed

- patients and in rats injected with aluminum chloride: relationship to impaired bone mineralisation. *J Clin Pathol* 1979; 32:832-44.
- 9 Goodman WG, Gilligan J, Horst R. Short-term aluminum administration in the rat: effects on bone formation and relationship to renal osteomalacia. *J Clin Invest* 1984; 73:171-81.
 - 10 Alfrey AC. Aluminum. *Adv Clin Chem* 1983; 23:69-91.
 - 11 Mehta RP. Encephalopathy in chronic renal failure appearing before the start of dialysis. *Can Med Assoc J* 1979; 120:1112-4.
 - 12 Andreoli SP, Bergstein JM, Sherrard DJ. Aluminum intoxication from aluminum-containing phosphate binders in children with azotemia not undergoing dialysis. *N Engl J Med* 1984; 310:1079-84.
 - 13 Sedman AB, Miller NL, Warady BA, Lum GM, Alfrey AC. Aluminum loading in children with chronic renal failure. *Kidney Int* 1984; 26:201-4.
 - 14 Klein GL, Alfrey AC, Miller NL, et al. Aluminum loading during total parenteral nutrition. *Am J Clin Nutr* 1982; 35:1425-9.
 - 15 Ott SM, Maloney NA, Klein GL, et al. Aluminum is associated with low bone formation in patients receiving chronic parenteral nutrition. *Ann Intern Med* 1983; 98:910-4.
 - 16 Sedman AB, Wilkening GW, Warady BA, Lum GM, Alfrey AC. Encephalopathy in childhood secondary to aluminum toxicity. *J Pediatr* 1984; 105:836-8.
 - 17 Alfrey AC. Aluminum intoxication. *N Engl J Med* 1984; 310:1113-5.
 - 18 Polinsky MS, Gruskin AB. Aluminum toxicity in children with chronic renal failure. *J Pediatr* 1984; 105:758-61.
 - 19 Klein GL, Ott SM, Alfrey AC, et al. Aluminum as a factor in the bone disease of long-term parenteral nutrition. *Trans Assoc Am Physicians* 1982; 95:155-64.
 - 20 Greger JL, Baier MJ. Excretion and retention of low or moderate levels of aluminum by human subjects. *Food Chem Toxicol* 1983; 21:473-7.
 - 21 Gorsky JE, Dietz AA, Spencer H, Osis D. Metabolic balance of aluminum studied in six men. *Clin Chem* 1979; 25:1739-43.
 - 22 Alfrey AC. Aluminum metabolism in uremia. *Neurotoxicology* 1980; 1:43-53.
 - 23 Wills MR, Savory J. Aluminum poisoning: dialysis encephalopathy, osteomalacia, and anaemia. *Lancet* 1983; 2:29-34.
 - 24 Kachny WD, Hegg AP, Alfrey AC. Gastrointestinal absorption of aluminum from aluminum-containing antacids. *N Engl J Med* 1977; 296:1389-90.
 - 25 Köhler L, Meeuwisse G, Mortenson W. Food intake and growth of infants between six and twenty-six weeks of age on breast milk, cow's milk formula or soy formula. *Acta Paediatr Scand* 1984; 73:40-8.

EVIDENCE FOR TWO SUBTYPES OF CUSHING'S DISEASE BASED ON THE ANALYSIS OF EPISODIC CORTISOL SECRETION

EVE VAN CAUTER, PH.D., AND SAMUEL REFETOFF, M.D.

Abstract To investigate the pathogenetic mechanisms of Cushing's syndrome, we studied variations in plasma cortisol levels (episodic variations, or pulses) over 24 hours in 51 normal subjects, 14 patients with adrenal adenoma, and 46 patients with Cushing's disease. Data were obtained both from our patients and from the literature.

As compared with normal subjects, patients with adrenal adenoma had fewer spikes in cortisol levels (defined as an elevation of at least 10 per cent and no less than 1 μg per deciliter), and the spikes were lower both in absolute terms (4.0 ± 1.8 vs. 5.1 ± 2.2 μg per deciliter, $P < 0.05$) and in terms of the percentage of the preceding trough concentration (23 ± 7 vs. 123 ± 74 per cent, $P < 0.001$).

Patients with Cushing's disease seemed to fall into two groups: those with hypopulsatile and those with hyperpul-

satile secretion. The hypopulsatile group had a normal number and absolute height of spikes, but their height relative to the preceding trough concentration was lower than in controls (42 ± 16 vs. 123 ± 74 per cent, $P < 0.005$). In contrast, the hyperpulsatile group had a similar number of spikes as the hypopulsatile group, but their absolute and relative heights were twice as great (12.7 ± 2.3 vs. 6.0 ± 1.6 μg per deciliter and 84 ± 40 vs. 42 ± 16 per cent, respectively; $P < 0.001$ for both).

We hypothesize that the Cushing's disease in the second group of patients may have been caused by increased hypothalamic release of, or pituitary responsiveness to, corticotropin-releasing factor, whereas that in the first group may represent pituitary oversecretion of corticotropin that is relatively independent of corticotropin-releasing factor. (*N Engl J Med* 1985; 312:1343-9.)

IN normal people, the adrenal gland secretes cortisol in a series of bursts rather than continuously.¹⁻³ Twenty-four-hour profiles of plasma cortisol concentrations measured in samples collected every 20 to 30 minutes typically show a jagged pattern with 7 to 10 "secretory spikes." This variation is usually referred to as episodic or pulsatile. On the average, plasma cortisol levels are highest in the early morning hours. Levels then decrease throughout the day, and there is a prolonged quiescent period around midnight. When plasma concentrations of the pituitary hormone corticotropin (ACTH) are measured along with cortisol in

the same samples, most cortisol spikes can be related to concomitant ACTH spikes.⁴ Although levels of hypothalamic corticotropin-releasing factor cannot be measured in human plasma, it is generally accepted that episodic increases in plasma ACTH and thus in cortisol are caused by intermittent release of corticotropin-releasing factor in the pituitary portal circulation.

Several reports have indicated that cortisol secretion remains episodic in Cushing's syndrome.^{5,6} On the basis of visual inspection of data, some investigators⁶ have concluded that the characteristics of episodic cortisol secretion do not differentiate patients with pituitary-independent Cushing's syndrome (i.e., adrenal adenoma or ectopic ACTH secretion) from those with pituitary-dependent Cushing's syndrome (Cushing's disease), whereas others⁷ have reported a reduced variability of plasma cortisol levels in patients with adrenal adenoma. Since the pulsatility of plasma

Dedicated to the memory of Dr. Dorothy T. Krieger.

From the Institute of Interdisciplinary Research, Free University, Brussels, Belgium, and the Thyroid Study Unit, Department of Medicine and Pediatrics, University of Chicago. Address reprint requests to Dr. Van Cauter at the Thyroid Study Unit, Box 138, University of Chicago, 5841 S. Maryland Ave., Chicago, IL 60637.

Supported in part by a grant (AM 15,070 RR 55) from the U.S. Public Health Service and by the APMO Foundation, Belgium.